Aeon Biopharma, INC. (AEON) — 8-K Filings

All 8-K filings from Aeon Biopharma, INC.. Browse 29 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (29)

AEON Biopharma Files 8-K: Agreements, Equity Sales — Dec 15, 2025 Risk: medium
AEON Biopharma, Inc. filed an 8-K on December 15, 2025, reporting on several key events. These include entering into a material definitive agreement, unregister
AEON Biopharma Files 8-K: Reg FD & Financials — Dec 4, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on December 4, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
AEON Biopharma Files 8-K on Agreements and Equity Sales — Nov 13, 2025 Risk: medium
AEON Biopharma, Inc. filed an 8-K on November 12, 2025, reporting on entering a material definitive agreement, unregistered sales of equity securities, and fina
AEON Biopharma Files 8-K — Sep 8, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on September 8, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Priveter
AEON Biopharma Files 8-K on Shareholder Vote Matters — Jun 13, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on June 13, 2025, to report on matters submitted to a vote of its security holders. The filing details the submission of speci
AEON Biopharma Files 8-K with Financials — May 20, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on May 20, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as
AEON Biopharma Faces Delisting Concerns — Apr 25, 2025 Risk: high
AEON Biopharma, Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, fo
AEON Biopharma Announces Director & Officer Changes — Apr 21, 2025 Risk: medium
AEON Biopharma, Inc. announced on April 19, 2025, changes related to its board of directors and executive compensation. The filing details the departure of cert
AEON Biopharma Announces Board and Officer Changes — Apr 8, 2025 Risk: medium
AEON Biopharma, Inc. announced on April 3, 2025, a change in its board of directors. Specifically, the company reported the departure of certain directors and t
AEON Biopharma Files 8-K on Director Changes & Compensation — Mar 27, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on March 27, 2025, reporting on the departure of directors or certain officers, the election of directors, and compensatory ar
AEON Biopharma Files 8-K for Reg FD and Financials — Mar 10, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on March 10, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
AEON Biopharma Files 8-K on Corporate Actions — Feb 24, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on February 24, 2025, reporting on several items including material modifications to security holder rights, amendments to its
AEON Biopharma Faces Delisting Concerns — Feb 7, 2025 Risk: high
AEON Biopharma, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company w
AEON Biopharma Files Current Report on Form 8-K — Jan 7, 2025 Risk: low
On January 6, 2025, AEON Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Priveterra Acquisition Corp., is incorpora
AEON Biopharma Files 8-K — Jan 6, 2025 Risk: low
AEON Biopharma, Inc. filed an 8-K on January 6, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
AEON Biopharma Files 8-K for Amendments and Financials — Dec 20, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on December 18, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, f
AEON Biopharma Files 8-K for Reg FD and Financials — Oct 7, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on October 7, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
AEON Biopharma Files 8-K on Operations — Aug 12, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
AEON Biopharma Files 8-K for Disclosure and Exhibits — Aug 6, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on August 6, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
AEON Biopharma Files 8-K — Jul 9, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on July 9, 2024, to report other events. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020,
AEON Biopharma Files 8-K on Security Holder Vote Matters — Jun 14, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on June 14, 2024, to report on the submission of matters to a vote of its security holders. The company, formerly known as Pri
AEON Biopharma Appoints New CMO, Director — May 16, 2024 Risk: medium
AEON Biopharma, Inc. announced on May 16, 2024, the appointment of Dr. Robert L. Ferris as Chief Medical Officer and the election of Ms. Sarah E. Empey to its B
AEON Biopharma Files 8-K with Financials and Updates — May 3, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on May 3, 2024, reporting on various events. The filing includes financial statements and exhibits, and is categorized under R
AEON Biopharma Withdraws Prior Financial Statements — May 3, 2024 Risk: high
AEON Biopharma, Inc. announced on May 1, 2024, that it will not rely on previously issued financial statements. This decision impacts financial reporting and ma
AEON Biopharma Closes $1.5M Private Placement — Apr 17, 2024 Risk: medium
AEON Biopharma, Inc. announced on April 12, 2024, the closing of a private placement of its common stock and warrants, raising approximately $1.5 million. The c
AEON Biopharma Files 8-K for Financials — Apr 15, 2024 Risk: low
AEON Biopharma, Inc. filed an 8-K on April 15, 2024, reporting on financial statements and exhibits. The company, formerly known as Priveterra Acquisition Corp.
AEON Biopharma Enters Material Definitive Agreement — Mar 28, 2024 Risk: medium
AEON Biopharma, Inc. entered into a material definitive agreement on March 24, 2024. This filing also indicates the creation of a direct financial obligation or
AEON Biopharma Files 8-K: Agreements, Sales, and Financials — Mar 19, 2024 Risk: medium
On March 18, 2024, AEON Biopharma, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company also discl
AEON Biopharma Flags Non-Reliance on Past Financials — Feb 16, 2024 Risk: high
AEON Biopharma, Inc. filed an 8-K on February 16, 2024, reporting that its previously issued financial statements, specifically those related to common stock an

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX